Nuclear medicine growth NRG PALLAS has deep experience in nuclear medicine materials and partnerships that support radiopharmaceutical development and production. Sales opportunities exist with pharma and biotech firms seeking reliable sources of medical isotopes, lead-212 access, and tightly integrated supply for clinical trials and commercial production.

Petten expansion Significant ongoing and planned expansions around the Pallas reactor project in Petten create cross-selling opportunities with equipment suppliers, service providers, and logistics partners. Potential buyers include manufacturers of reactor protection systems, irradiation services, and related safety and infrastructure solutions.

Strategic partnerships Active collaboration with Framatome, TAG1, Morpho Pharma, and Curium indicates a client-centric commercial model open to multi-year, multi-party contracts for isotopes, radiopharmaceuticals, and Mo-99 supply. Target roles include procurement, supply chain, and clinical development executives seeking dependable, diversified sourcing.

Nuclear energy transition NRG PALLAS positions itself as a supplier enabling CO2-neutral energy and climate solutions. This aligns with utility and energy companies seeking nuclear-enabled baseload capacity, irradiation services for material testing, and regional partners pursuing low-carbon energy portfolios.

Leadership transition Executive director changes at Nuclear Energy Services signal potential open doors for strategic governance discussions, new service line introductions, or collaboration models with Urenco and other industry players. Engage with executive-level buyers overseeing energy services and strategic partnerships.